BIOLOGICS US 2024
BY OXFORD GLOBAL

Book Now

October 03 - 04 2024 | San Diego, CA

Driving the discovery & development of safe, effective & innovative biologic drugs through streamlined discovery, clinical and analytical strategies

6 Content Tracks

70+ Hours of 1:1 Meetings

15+ Partners

300+ Attendees

Thank You To Our Gold Sponsors

AJINOMOTO BIO•PHARMA SERVICES

Waters™ | TA Instruments

50+ Industry-Leading Speakers Including...

OLIVIER KITTEN, Founder and Chief Executive Officer, Affilogic

HANS VAN DER VLIET, Chief Scientific Officer, LAVA Therapeutics

LINDA HORNER, Chief Administrative Patent Judge, Patent Trial and Appeal Board, USPTO

PURBASA PATNAIK, Associate Director, Drug Product Manufacturing & CMC Biotherapeutics, Exelixis

AMITA DATTA-MANNAN, Associate Vice President & Clinical Team Leader, Eli Lilly

NATALIE GRINSHTINE Director - ADC Discovery, Pfizer

MATT CHU, Director Research, Protein Engineering, Astellas

MIKE SCHOPPERLE, Chief Executive Officer, CureMeta

KIM JANDA, Professor & Director, Scripps Research Institute

WELCOME TO

Biologics US 2024

Committed to accelerating novel biologic products to market, the Biologics Series is landing on the West Coast to provide you with intimate networking opportunities and curated content on the most critical advances in the biologics industry.

Biologics have come to the forefront of the pharmaceutical industry, with ever-increasing demand for large molecule products, but their development still presents unique and complex challenges from both technical and regulatory perspectives. Following the success of our industry renowned NextGen BioMed Congress, Biologics US brings together 300+ leaders from across the North American biologics industry to discuss the innovative strategies and technologies needed to enable more effective biological products to enter the market.

Eszter Sutowski Nagy,
Director of Editorial & Event Content,
Oxford Global

3 High-Level Events in 1

Biologics US features three co-located conferences:

- Proteins & Antibodies Congress
- ADC Discovery & Development Congress
- Peptides Congress

Through providing access to three events in one, we seek to champion interdisciplinary conversations across the entire industry. Alongside innovative presentations, our curated programme allows for in-depth networking – fostering new partnerships that will advance your pipeline and help you translate your innovative target from bench to bedside.

Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things Biologics

Click Here

LinkedIn
@OGConferences

WHAT'S NEW

Benefits Of Attending

Why Attend?

- **Hear innovative content from leaders in their fields.** With multiple tracks each day, the agenda is bursting with keynotes, panels, and case study presentations covering the most interesting data in protein & antibody engineering, next-generation antibody therapeutics, peptide design and more
- **Uncover the next generation of biologics research** and gain the insights you need to overcome the challenges of identifying and validating novel new targets, including multi-specifics, cell engagers, ADCs and peptides
- **Gain a comprehensive understanding of AI/ML-guided protein & antibody engineering.** With new approaches such as Generative AI allowing for more rapid and efficient antibody discovery & design than ever before, learn how to effectively integrate new algorithms into your workflows
- **Connect with 300+ biopharma and academic leaders** who are actively prioritizing biologic targets to share solutions on the key challenges of working with these modalities, via interactive roundtables, our 1:1 partnering system and networking sessions
- **With new tools & platforms always under development,** our exhibition hall highlights the most promising products to help you meet your research goals and progress your targets towards the clinic

"This conference is fantastic for being able to really reach our target audience: people that are just as invested in looking at different ways to evolve their processes. To have that exposure that allows us to communicate with them effectively is a no brainer."

- CINDY GERSON, SENIOR LEAD PRODUCT MANAGER, SCHRÖDINGER

MERCK

"Excellent combination of current topics in the biologics field, experienced industry representatives and academic researchers."

- DIRECTOR, CELL-BASED ASSAYS, MERCK

WHY PARTNER WITH
OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalized experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings
Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities
Showcase your company's recent work to a relevant and highly engaged audience.

Host Panel & Roundtable Discussions
Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops
Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions
Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation
Accessing the Oxford Global database, amplify your thought leadership and branding messaging through a post-event case study e-Book.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH
Who Is Partnering?

Gold Sponsors
Ajinomoto · BIO•PHARMA SERVICES · Waters™ | TA Instruments™

Silver Sponsors
Alloy Therapeutics® · ABZENA · DelSiTech · MaxCyte® · PipeBio · SCIEX The Power of Precision · sphere FLUIDICS

Bronze Sponsors
Cradle · GeneFrontier · GenScript Make Research Easy · NOF · UNCHAINED LABS

Network & Programme Sponsors
BIOINTRON · evitria your proteins, reliably delivered · FORMULATRIX® · HAMILTON · nicoya · QUANTUM SI · Selvita · SGS

Book Now

LinkedIn
@OGConferences

NETWORK & KNOWLEDGE-SHARE

Attendees

300+ VPs, Directors & Senior Managers will be attending on-site and online, coming from leading healthcare, biotech, pharma & research institutions in the following fields & more

- Antibody Engineering
- Protein Engineering
- Bioanalytical Development
- Protein Expression
- Computational Biology
- Antibody Discovery
- Peptide Design
- Peptide Chemistry
- Oligo Discovery
- Oligo Chemistry
- Next-Generation Biologics
- Antibody-Drug Conjugates

Formal & informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meetings will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Engineering Platforms
- Bioconjugation
- Antibody Generation
- Bispecific Antibody Design
- Characterization Tools
- Developability Assessment
- Expression Platforms
- Conjugation Technologies
- Display Technologies
- Modelling Platforms
- Delivery Platforms
- Green Solvents

Attended by these companies & many more:

Lilly, Pfizer, AMGEN, GSK GlaxoSmithKline, CureMeta Antibody Therapeutics for Metastatic Cancer, Astellas, Genentech A Member of the Roche Group, sanofi, MERCK, LAVA Therapeutics, Bristol Myers Squibb, REGENERON, PYXIS ONCOLOGY, affilogic, abbvie

Previous Attendee Profile:

Function



Geography



Sector



LinkedIn
@OGConferences

GAIN EXPERTISE FROM THOUGHT LEADERS

Confirmed Speakers

KEY SPEAKERS

Day One

OLIVIER KITTEN,
Founder and Chief Executive Officer, Affilogic

Day One

HANS VAN DER VLIET,
Chief Scientific Officer, LAVA Therapeutics

Day Two

LINDA HORNER,
Chief Administrative Patent Judge, Patent Trial and Appeal Board, USPTO

Day Two

PURBASA PATNAIK, Associate Director, Drug Product Manufacturing & CMC Biotherapeutics, Exelixis



Day One

AMITA DATTA-MANNAN,
Associate Vice President & Clinical Team Leader, Eli Lilly

Day Two

NATALIE GRINSHTINE
Director - ADC Discovery, Pfizer

STEVEN BALLET
Professor, Departments of Chemistry and Bio-Engineering Sciences, Vrije Universiteit Brussel

ANDREW VENDEL
Senior Director, Immunology, Eli Lilly

MARIA HEDLUND
Principal Scientist, Toxicology, Avidity Biosciences

MATT CHU
Director Research, Protein Engineering, Astellas

CHRISTOPHER HART
Chief Executive Officer, Creyon Bio

KIM JANDA
Professor, Department of Chemistry, Director, The Worm Institute of Research & Medicine (WIRM), Scripps Research Institute

JINQUAN LOU
Director, Janssen

YI XING
Senior Director, Seismic Therapeutics

HANS VAN DER VLIET
Chief Scientific Officer, LAVA Therapeutics

AMITA DATTA-MANNAN
Associate Vice President & Clinical Team Leader, Eli Lilly

OLIVIER KITTEN
Founder and Chief Executive Officer, Affilogic

MIKE SCHOPPERLE
Chief Executive Officer, CureMeta

SUK HYUNG
Senior Principal Scientist, Genentech

MICHAEL SIERKS
Professor, Arizona State University

BRIAN AVANZINO
Principal Scientist, Amgen

DANIEL KIRCHHOFER
Senior Fellow, Genentech

SASHA EBRAHIMI
Principal Investigator & Associate Fellow, GSK

LIAN YI
Principal Scientist, Genentech

RAJIKA PERERA
Chief Executive Officer, Poseidon LLC

UDAYA RANGASWAMY
Director, Translational Biology, Rondo Therapeutics

JEFFREY LEYTON
Associate Professor, University of Ottawa

PHILIP KIM
Professor / Principal Investigator, University of Toronto

NATALIE GRINSHTEIN
Director – ADC Discovery, Pfizer

PURBASA PATNAIK
Associate Director, Drug Product Manufacturing & CMC Biotherapeutics, Exelixis

WEI WANG
Professor, UCSD

JACK OSTROWSKI
Director Protein Sciences, Avidity Biosciences

MICHAEL COCHRAN
Director Chemistry, Avidity Biosciences

JAY JONES
Senior Research Associate, Pfizer

JAN SCHNITZER
Chief Executive Officer & President, PRISM

JULIE BEAUDET
CMC Senior Staff Scientist, Regeneron

UMER HASSAN
Associate Professor, Rutgers University

MIMMI BALLARD
Director, Analytical Development & Quality Control, Bioassays, VIR Biotechnology

ALAN WAHL
Chief Executive Officer, Abacus Biosciences

DENISE STECKEL
Head Of Clinical Collaborations Development, Genetech

PAUL RICHARDSON
Director Discovery Chemistry, Pfizer

NAZNEEN DEWJI
Chief Executive Officer, Cenna Biosciences

CAITLIN MATERSON
Director, Technical Development Gilead Sciences

DAY ONE OVERVIEW

Thursday 03 October 2024

Alongside the presentations, the conference features a host of roundtables and panels – enabling you to deep-dive into specific pain points and form meaningful connections. Day 1 sessions include:

- ADC Target Selection
- Using The Right Tools For ADC Characterization

EXPLORE CURATED & INSIGHTFUL CONTENT

Agenda At A Glance

Track 1: Antibody Discovery, Engineering & Analysis

- Novel engineering strategies to enhance antibody functions
- Advanced technologies for new antibody discovery
- Optimized tools for characterization and bioanalysis

Track 2: NextGen Therapeutics – Multispecifics, Cell Engagers, & Other New Modalities

- Case study presentations on the next generation of antibody therapeutics
- Innovative strategies for the identification & validation of new targets
- Novel therapeutic indications for antibodies

Track 3: Engineering Conjugates to Enhance Therapeutic Potential

- Optimizing design of ADC for specific targets
- Linker/payload technologies for better therapeutic index
- Minimizing molecule toxicity, including off-target toxicities

Book Now

LinkedIn

@OGConferences

DAY TWO OVERVIEW

Friday 04 October 2024

Alongside the presentations, the conference features a host of roundtables and panels – enabling you to deep-dive into specific pain points and form meaningful connections. Day 2 sessions include:

- A Multi-Pronged Strategy For A Multipartite Molecule: The IP Space For ADCs
- Understanding When & How To Scale Up CMC Effectively

EXPLORE CURATED & INSIGHTFUL CONTENT

Agenda At A Glance

Track 1: Computational Tools, AI/ML-Guided Engineering

- Rational protein design via structure-based tools
- Computational advances in protein engineering
- AI-driven antibody design & optimization

Track 2: ADC Translational, Clinical & Manufacturing Lessons

- Preclinical models to bring ADCs to the clinic
- Progression into the clinic through effective biomarkers
- Best practices for ADC-combination clinical research
- Streamlining ADC process development
- CMC strategies for effective ADC development

Track 3: Peptide Discovery, Formulation & Development

- Discovery & optimization of peptide therapeutics
- Peptide design for various therapeutic targets
- Biology & application areas: Infectious diseases, vaccines, oncology

DAY ONE: OCTOBER 03 2024

09:00 **Oxford Global's Welcome Address**

09:10 **Keynote Address: Bispecific Gamma-Delta T Cell Engagers For Cancer Immunotherapy**

Presentation will focus on the preclinical and early clinical development of bispecific Vγ9Vδ2-T cell engagers as a novel approach for cancer immunotherapy.

HANS VAN DER VLIET, Chief Scientific Officer,
LAVA Therapeutics

PROTEINS & ANTIBODIES CONGRESS

ADC DISCOVERY & DEVELOPMENT CONGRESS

TRACK 1: ANTIBODY DISCOVERY, ENGINEERING & BIOANALYSIS

Track Chair:
POSITION AVAILABLE

TRACK 2: NEXTGEN THERAPEUTICS – MULTISPECIFICS, CELL ENGAGERS, & OTHER NEW MODALITIES

Track Chair:
DONGXING ZHA, Chief Technology Officer, TCR Discovery and Engineering,
Alloy Therapeutics

TRACK 3: ENGINEERING CONJUGATES TO ENHANCE THERAPEUTIC POTENTIAL

Track Chair:
JULIE BEAUDET, CMC Senior Staff Scientist,
Regeneron

9:35

Identifying Agonist Antibodies To Inhibit Immune Response For Autoimmune Diseases

We at Lilly have developed agonist antibodies to the Checkpoint Inhibitory Receptor (CIR) BTLA for the treatment of autoimmune diseases

ANDREW VENDEL, Senior Director, Immunology,
Eli Lilly

Advanced Cellular Control through Engineered Ligands (ACCEL™) ConvertibleCAR™ Platform

MATT CHU, Director Research, Protein Engineering,
Astellas

Development Of A Novel Muscle Targeted Antibody Oligonucleotide Conjugate For The Treatment Of Myotonic Dystrophy Type 1

- Overview of Antibody Oligonucleotide Conjugate (AOC™) Platform
- Del-desiran Preclinical Pharmacology
- Del-desiran Nonclinical Development Package
- Del-desiran MARINA™ Phase 1/2 Proof of Concept Trial

MARIA HEDLUND, Principal Scientist, Toxicology,
Avidity Biosciences

Q&A session & transition time between conference rooms

10:00

Engineered Human-Antibody Fragment For Reversing Synthetic Opioid Respiratory Depression

- Over 100,000 people in the US have succumbed to drug overdose in 2021, with 75% of these related to opioids.
- Treatment for synthetic opioid overdose creates problematic challenges due to their unique pharmacological properties
- Engineered antibodies that can sequester synthetic opioids provide an alternative/complementary approach for reversing opioid-induced overdose.

KIM JANDA, Professor, Department of Chemistry, Director, The Worm Institute of Research & Medicine (WIRM),
Scripps Research Institute

Beyond Antibodies: A Simplified Protein Modality For Targeting Solid Tumours

Our technology is designed to rapidly generate bispecific therapeutics with various novel and existing moieties such as nanobodies, scFvs, and non-antibody domains in a "LEGO"-like manner to generate TCEs. The TCEs have very high safety profiles compared to conventional biologics and low pro-inflammatory cytokines. In vivo efficacy has been demonstrated in NSCLC mouse models

RAJIKA PERERA, Chief Executive Officer,
Poseidon LLC

Pre- Recoded Talk: Reducing Target Binding Affinity Improves The Therapeutic Index Of Anti-MET Antibody Drug Conjugate In Tumor Bearing Animals

- Decreasing the target binding affinity anti-mesenchymal-epithelial transition factor (MET) monomethyl auristatin E (MMAE) ADC reduces the TMDD to MET expressed in normal tissues while maintaining anti-tumor activity and providing an ~3-fold larger therapeutic index for MET-ADC
- The integrated approach of optimizing ADC target affinity can be applied to a wide range of targets as a platform-based method to improve the clinical outcomes for ADCs

AMITA DATTA-MANNAN, Associate Vice President & Clinical Team Leader,
Eli Lilly

10:25 **MORNING BREAK** | 1-2-1 Meetings x4 | Poster Displays

11:45

New High Throughput Method For Measuring The Thermal Stability Of Biotherapeutics

This presentation introduces a novel high throughput method for assessing the thermal stability of biotherapeutics using advanced differential scanning calorimetry (DSC). This method is geared towards the biopharmaceutical industry with low volume, high concentration samples and offers a new dimension in DSC technology.

NEIL DEMARSE, Senior Manager - Product Solutions,
TA Instruments - Waters

Next-Generation Protein Sequencing: A New Era Of Biologics Screening & Characterization

JOEL MCDADE, Senior Manager of Business Development
Quantum-Si

Versatile & Robust Chemical Conjugation Platform: AJICAP® Technologies

Our group developed site-specific conjugation of antibodies and hydrophilic linker for ADCs which enable therapeutic window enhancement. We will show examples of applications to novel antibody conjugates as well.

TOMOHIRO WATANABE, ADC Project Manager,
Ajinomoto Bio-Pharma

Q&A session & transition time between conference rooms

DAY ONE: OCTOBER 03 2024

	TRACK 1: ANTIBODY DISCOVERY, ENGINEERING & BIOANALYSIS	TRACK 2: NEXTGEN THERAPEUTICS – MULTISPECIFICS, CELL ENGAGERS, & OTHER NEW MODALITIES	TRACK 3: ENGINEERING CONJUGATES TO ENHANCE THERAPEUTIC POTENTIAL
12:10	**Application Of Quantitative Immunoaffinity LC-MS/MS Assay To Understand Biotherapeutic Stability & Biotransformation** • Diversification of ADC constructs requires an suite of bioanalytical assays for ADCs • Conjugation chemistry will inform the analyte selection • PK AND Biotransformation of ADCS SUK HYUNG, Senior Principal Scientist, **Genentech**	**Costimulatory Bispecific Antibodies For The Treatment Of Solid Tumors** • Therapeutic treatment of solid tumors with CD3-based T cell engagers has been challenging due to on-target off-tumor toxicity concerns or due to a suppressive tumor microenvironment • Rondo's bispecific platform is designed to specifically engage costimulatory receptors in the tumor microenvironment to enable a robust T cell response • We present preclinical data on our lead candidate RNDO-564, a CD28 and Nectin-4 targeted bispecific antibody for the treatment of metastatic bladder cancer UDAYA RANGASWAMY, Director, Translational Biology, **Rondo Therapeutics**	**Validating Novel Targets To Maximize The Efficacy Of ADCs** • Over 90% of patients with solid tumors die from metastasis of the disease. Pancreatic and gastric cancers alone are responsible for over 600,000 deaths worldwide per year. The reason for this is the lack of good therapeutic drugs to treat aggressive and metastatic cancer. • CM-14, is a first-in-class humanized ADC for patients with metastatic pancreatic and gastric cancers. • CM-14 is highly specific to a novel embryonic cancer target TRA-1-60 • Strong scientific evidence shows TRA-1-60 positive cancer cells within solid tumors are responsible for the progression, resistance and metastasis of the disease. Strong preclinical CM-09 efficacy studies justify the next step underway to complete a human clinical trial MIKE SCHOPPERLE, Chief Executive Officer, **CureMeta**
	Q&A session & transition time between conference rooms		
12:35	**TDiscovering Ultra-Low Dose therapy Via Precision Transvascular Pumping Of Antibodies & Nanoparticles** • 90% of lethal diseases and known therapeutic targets occur inside solid tissues with barriers that restrict passive drug penetration, target accessibility and therapeutic efficacy • Discovery to optimize delivery targets and pumping mechanisms across key barriers can create deliver systems to target and penetrate single tissues and tumors • Ex., >50% of iv injected antibodies, even when conjugated to nanoparticles, can be pumped to concentrate inside lung and avoid RES • Targeting the pumping system properly can increase precision targeting by 100-fold and drug potency by 1000-fold JAN SCHNITZER, Chief Executive Officer & President, **PRISM**	**Tailoring Processing Of The Amyloid Precursor Protein To Restore Neuronal Proteostasis In Neurodegenerative Diseases** • Use novel proteolytic bispecific antibody to alter processing of amyloid precursor protein • Selectively promote neuroprotective pathways • Selectively inhibit neurotoxic pathways • Restore neuronal health in mouse model MICHAEL SIERKS, Professor, **Arizona State University**	**Interconnecting Biology and Deep Learning for Advancing ADC Design and Efficacy** • ADCs face a significant lack of chemical diversity and experience high attrition failure rates • The interplay between tumor biology and ADC design remains poorly understood, further complicating and amplifying the uncertainty in the critical early stages of ADC preclinical development • We have developed a holistic deep learning platform that uniquely incorporates complex biology underlying ADC cytotoxin delivery and tumor cell response, including both effectiveness and resistance. JEFFREY LEYTON, Associate Professor, **University of Ottawa**
13:00	LUNCH BREAK & REFRESHMENTS	1-2-1 Meetings x3	Poster Displays
14:00	**Optimizing Bioprocess Development Decisions With Next-Generation Analytical Techniques** Detailed and accurate information about a molecule's characteristics is critical for production. This data allows scientists to make informed decisions, pushing the strongest drug candidates forward, while maintaining a competitive pace. Recent advances in analytical techniques have enhanced the speed and reliability of data collection, making it easier to gather critical insights. Here, we explore case studies, demonstrating how SCIEX solutions support the development of biopharmaceuticals from routine analysis to deep characterization of PQAs. HENRY KANG, Market Development Manager - Capillary Electrophoresis, **SCIEX**	**Keyway TCR-like Antibody (TCR mimic) Discovery: Fully Integrated Workflow To Get from Target Idea to Highly Specific & Functional Lead Candidate** TCR mimics enables targeting of intracellular proteins that cannot be addressed by conventional cancer immunotherapies. Keyway TCRm Discovery Services has successfully delivered fully functional and highly specific TCRm candidates to 9+ partners DONGXING ZHA, Chief Technology Officer at Alloy Therapeutics & Chief Executive Officer, Keyway TCR Discovery, **Alloy Therapeutics**	**Leveraging Stage Appropriate Cytotoxicity Assays To Develop Successful Biologics & Bioconjugates** Bioassays are a fundamental component of drug development and allow the assessment of a wide variety of properties from basic functionality and mechanism of action through to assessment of immunogenicity risk and safety. As the diversity and complexity of biologics and bioconjugates expand, choosing the most appropriate assay format at different stages of development becomes of utmost importance. Here we present solutions for early screening, detailed characterization, as well as lot release testing. We summarize the benefits and challenges of different approaches, and present case studies for various modalities ERIKA KOVAC, Senior Director, Bioassay, **Abzena**
	Q&A session & transition time between conference rooms		
14:25	**Picodroplets For Biologics Discovery & Scale Up: A Novel Automation Approach** Ultra-miniaturized droplet microfluidics provides a powerful approach to enable efficient discovery and scale up of biologics. In this talk, we will introduce the underlying approach and show how this has been integrated into a complete automated system for everyday use in the translational research process. We will give examples of the technology in action and highlight compelling new functionality and techniques to extend its application. SIMONA PREIKSAITE, Senior Field Application Scientist, **Sphere Fluidics**	*Delegates are welcome to attend co- located events*	**Give Your ADCs The Stamp Of Approval With High-Throughput Characterization** ADCs are powerful but they're tricky to characterize. The right low-volume, high-throughput tools make it easy to uncover their secrets. Join my talk and see how our solutions help you quantitate ADCs, check DAR, spot aggregation or unfolding, and optimize formulations. ROSS WALTON, PhD Senior Applications Scientist **Unchained Labs**
	Q& A session & transition time between conference rooms		

DAY ONE: OCTOBER 03 2024

	TRACK 1: ANTIBODY DISCOVERY, ENGINEERING & BIOANALYSIS	TRACK 2: NEXTGEN THERAPEUTICS – MULTISPECIFICS, CELL ENGAGERS, & OTHER NEW MODALITIES	TRACK 3: ENGINEERING CONJUGATES TO ENHANCE THERAPEUTIC POTENTIAL
14:50	**Panel Discussion:** Using The Right Tools For ADC Characterization • Emerging methods for bioanalysis • Immunogenicity considerations • Hydrophobicity limitations **Panellists:** AMING ZHANG, Senior Director, Head of Analytical & QC, **Pyxis Oncology** SHAWN OWEN, Assistant Professor of Molecular Pharmaceutics **The University Of Utah** SIMON LETARTE, Director, **Gilead Sciences**	**T Cell Engager Engineering Approaches For An Improved Therapeutic Index In Solid Tumors** • T cell engager (TCE) molecules exhibit a potent mechanism of action • Tumor-selective targets are rare, and on-target off-tumor toxicity can be a challenge for TCE development in solid tumors • Novel approaches are needed for solid tumor targets that would otherwise be hindered by on-target off-tumor toxicity BRIAN AVANZINO, Principal Scientist, **Amgen**	**Tuning The Higher Order Structure Of ADCs By Traversing The Formulation Design Space** SASHA EBRAHIMI, Principal Investigator & Associate Fellow, **GSK**
	Q&A session & transition time between conference rooms		
15:15	**From scFv to spFv: Stapling scFv For Multispecific Biotherapeutics Of Superior Properties** Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains exhibit lower stability and increased risk of aggregation due to transient dissociation (“breathing”) and inter-molecular reassociation of the two domains (VL and VH). We designed a novel strategy, referred to as stapling, that introduces two disulfide bonds between the scFv linker and the two variable domains to minimize scFv breathing. We named the resulting molecules stapled scFv (spFv). Stapling increased thermal stability (Tm) by an average of 10°C. In multiple scFv/spFv multispecifics, the spFv molecules display significantly improved stability, minimal aggregation and superior product quality. These spFv multispecifics retain binding affinity and functionality. Our stapling design was compatible with all antibody variable regions we evaluated and may be widely applicable to stabilize scFv molecules for designing biotherapeutics with superior biophysical properties. JINQUAN LUO, Director, **Janssen**	**Utilizing CD180 For Antigen-Specific Immune Responses** Abacus is developing CD180-targeted therapies to treat autoimmune disease and solid cancers. Agonists to CD180, a key regulator of immune antigen-presenting cells, increase polyclonal Ig and reduce inflammatory cytokines in autoimmune disease. In contrast, antigen-fused CD180 agonists invoke highly antigen-specific humoral and T cell responses effective against established tumors ALAN WAHL, Chief Executive Officer, **Abacus Bioscience**	**Panel Discussion:** ADC Target Selection • Emerging strategies & novel approaches • Target ID/validation • Proteomic & bioinformatic technologies **Panelists:** YANG SU, Principal Scientist, **Bristol Myers Squibb** JAN SCHNITZER, Chief Executive Officer & President, **PRISM** SON LAM, Senior Director, **Avidity Bio**
	Q&A session & transition time between conference rooms		
15:40	**Biological Characterization Of mAbs With Complex Mechanisms of Action** • Introduction to mAbs targeting infectious diseases and how they utilize the immune system • Early and late stage potency strategy using orthogonal methods • Challenges in developing assays that are robust yet sensitive to process changes MIMMI BALLARD, Director, Analytical Development & Quality Control, Bioassays **VIR Biotechnolgoy**	**Insights Into Successful Industrial Clinical Collaborations** The presentation will provide insight into the unique and interesting landscape of combination trials. These combination trials are in joint ventures without side companies to Genentech/Roche. We will cover the need for combination studies, the unique team structure and successes and challenges with specific kinds of combinations. • Why do we establish clinical collaborations with external companies? • Industry Clinical Collaborations (ICC) at Roche • Drugs combinations in ICC • Successes & challenges with commercial drugs & novel / novel combinations DENISE STECKEL, Head Of Clincal Collaborations Development, **Genentech**	
16:05	AFTERNOON BREAK | 1-2-1 Meetings x4 | Poster Displays		
17:25	**Empowering Antibodies Using Nanofitins** Multispecific biologics are an alternative to cocktails, of particular interest when (i) co-engagement is required or (ii) more than 2 moieties are needed. Nanofitins are small affinity scaffolds of which multiple instances can be fused with biologics such as mAbs. They constitute a streamlined approach to build multispecific biotherapeutics OLIVIER KITTEN, Founder and Chief Executive Officer, **Affilogic**	**Accommodating Nonstandard mAb Formats in an Early-Phase CMC Platform Approach; Achieving Speed to Clinic When One Size Does Not Fit All** CAITLIN MASTERMAN, Associate Director, Technical Development, **Gilead Sciences**	**Development of a Platform Cysteinylation Protocol for ThioMab Charge Assay** • Thiomabs’ charge profile is masked by heterogeneity of Cys and GSH cap om engineered cysteines • A platform cysteinylation protocol was developed for thiomabs’ charge assay LIAN YI, Principal Scientist, **Genentech**
17:50	**Networking Drinks & End of Day One**		

DAY TWO: OCTOBER 04 2024

08:45

Roundtable Discussion 1: Novel Design Of Next Generation ADCs

- **Next Generation ADC with cytotoxic payloads**
- Multispesfic targeting antibodies
- ADCs with dual and multipule payloads
- Novel linkers and payloads
- **Next Generation ADCs Beyond Cytotoxic Payloads**
- Degarder ADCs
- Oligonucleotides & peptides

Moderator: YUAN CHENG, Director of Hybrid Modality, **Amgen**

Roundtable Discussion 2: Pre-Clinical Development Considerations For ADCs

- **ADC Development Pathway Overview**
- **Target Selection and Antibody Production**
- **Payload / Linker / Conjugation / Formulation Impact**

Moderator: NATHAN ALVES, Associate Professor & Director of Translational Research Emergency Medicine, **Indiana University School of Medicine**

09:15

Keynote Address: Maximizing the Efficacy of ADCs: Focus On Target Selection &Pairing With The Right Payload

• Background - the renaissance of ADCs
• Target selection process and reasons behind the choice of pursuing various clinical targets
• Considering reverse translation in the target selection process – lessons learned from the clinic

NATALIE GRINSHTEIN, Director, ADC Discovery,
Pfizer

TRACK 1: COMPUTATIONAL TOOLS, AI/ML-GUIDED ENGINEERING

Track Chair:
ELI BIXBY, Co-Founder, Head of Machine Learning,
Cradle

09:45

Track Keynote Address: Machine Learning Based Design of Proteins, Antibodies & Peptides

- Machine learning based methods for protein design
- Score-based generative models (SGMs, continuous time diffusion models) for protein and antibody design
- Methods to directly learn the conformational states of peptides
- DApplications for macrocycle design

PHILIP KIM, Professor / Principal Investigator,
University of Toronto

10:10

Advancing Data-Driven Decision Making For Therapeutic Candidate Selection With In Silico Tools

Introducing antibody developability analysis early on in the process of antibody hit selection can ideally reduce the time and resources required for hit selection campaigns. We present possible avenues in silico screening techniques for qualifying promising binders by screening for less aggregation-prone antibodies.

JANNICK BENDTSEN, Chief Executive Officer,
PipeBio

TRACK 2: TRANSLATIONAL, CLINICAL & MANUFACTURING LESSONS

Track Chair:
POSITION AVAILABLE

Track Keynote Address: Overcoming Hurdles: Development & Manufacturing Challenges Of Antibody Drug Conjugates (ADCs)

Currently, ADCs are among the most rapidly advancing cancer treatments due to their precision in delivering powerful cytotoxic agents directly to tumor cells, minimizing unwanted side effects. Despite their recent achievements, ADCs present various technical and manufacturing hurdles. This presentation will delve into the challenges faced by CMC in the development and production of ADC drug products, as well as potential solutions

PURBASA PATNAIK, Associate Director, Drug Product Manufacturing & CMC Biotherapeutics,
Exelixis

Q&A session & transition time between conference rooms

Accelerate ADC Development With MaxCyte Electroporation & Transient Gene Expression

MaxCyte's advanced electroporation technology enables large-scale transient gene expression for accelerated antibody production for ADC development. Our platform delivers high yields and reproducible results, supporting rapid manufacturing and commercialization of novel therapies.

JERALDINE MENDOZA, Senior Scientist, Process Development,
MaxCyte

TRACK 3: PEPTIDE DISCOVERY, FORMULATION & DEVELOPMENT

Track Chair:
NAZNEEN DEWJI, Chief Executive Officer,
Cenna Biosciences

Track Keynote Address: NubytideTM, a first-in-class, disease-modifying peptide for the prevention and treatment of Alzheimer's disease

• Nubytide blocks processing of the Amyloid precursor protein APP to Aβ
• Novel, differentiated approach that does not target or affect β- or □-secretase activities
• Addresses problems of failed secretase inhibitors and current FDA-approved monoclonal antibody drugs
• Ready for IND and Phase-1 clinical trials

NAZNEEN DEWJI, Chief Executive Officer,
Cenna Biosciences

Cutting-Edge Releasable PEG, SUNBRIGHT® BD Series, For Peptide Therapy

In this presentation, we will introduce the effectiveness of PEGylated peptide by releasable PEG comparison with PEGylated peptide by non-releasable PEG based on the results of in vitro and in vivo assay.

SATOSHI KISHIDA, Research Scientist,
NOF Corporation

DAY TWO: OCTOBER 04 2024

	TRACK 1: COMPUTATIONAL TOOLS, AI/ML-GUIDED ENGINEERING	TRACK 2: TRANSLATIONAL, CLINICAL & MANUFACTURING LESSONS	TRACK 3: PEPTIDE DISCOVERY, FORMULATION & DEVELOPMENT
		Q&A session & transition time between conference rooms	
10:35	**Next-Gen Antibody Engineering For GPCRs By Integrating Autonomous Yeast Display & AI** Traditional antibody generation is often slow and costly. AuraQuest™ utilizes yeast surface display and autonomous hypermutation to mimic animal immunization, enabling rapid antibody discovery. Combined with the AI platform AuraPicasso™, this approach accelerates the engineering of antibodies with specific characteristics. This method has effectively targeted challenging antigens like GPCRs, demonstrating potent nanobody isolation within two weeks through affinity maturation using yeast culturing and FACS ALON WELLNER, Vice President of Biology, **Aureka Biotechnologies** GenScript Make Research Easy	**Silver Solution Provider Presentation** *Delegates are welcome to attend co- located events*	**Long- Acting Delivery Of Biologics: Biodegradable Silica Matrix** DelSiTech Silica Matrix is a biodegradable silica composite technology that enables the highly controlled release of target molecules. The technology is being applied to biological entities from peptides to large proteins across a wide range of therapeutic areas and routes of administration, such as subcutaneous and intravitreal injections. In this presentation, we will explore the capabilities and features of the technology to stably deliver biological entities, including the ability to avoid burst release. MARCUS REAY, Director, Business Development, **DelSiTech** DelSiTech
11:00	MORNING BREAK — 1-2-1 Meetings x3 — Poster Displays		
12:00	**Rebuilding Expression System & Its Applications For R&D Of Biologics.** PURExpress is our unique rebuilt cell-free protein expression system. It's easy to customize for various applications, and useful for high throughput screening of various kinds of biologics, difficult-to-express protein or novel modalities having the synergy with the AI/ML platform TAKASHI EBIHARA, Chief Operating Officer, **GeneFrontier Corporation** GeneFrontier	**Bronze Solution Provider Presentation** *Delegates are welcome to attend co- located events*	**Bronze Solution Provider Presentation** *Delegates are welcome to attend co- located events*
		Q& A session & transition time between conference rooms	
12:25	**Cradle's Active Learning Approach For Optimization Of Antibodies & Other Therapeutic Proteins** An intro to Cradle's active learning approach for therapeutic protein optimization. Using antibody case studies, Eli Bixby will highlight the value of key parts of Cradle's methodology that overcome the limitations of zero-shot generative methods. ELI BIXBY, Co-Founder and Head of Machine Learning Research, **Cradle** Cradle	**Bronze Solution Provider Presentation** *Delegates are welcome to attend co- located events*	**Bronze Solution Provider Presentation** *Delegates are welcome to attend co- located events*
		Q& A session & transition time between conference rooms	
12:50	**Application Of AI/ML & Deep Learning Tools In Antibody Engineering** WEI WANG, Professor, **UCSD**	*Delegates are welcome to attend co- located events*	**Engineering Oligonucleotide-Based Medicines - Moving Beyond Slow & Failure-prone Trial-and-Error Drug Discovery** • **Overview of the Creyon™ Platform that allows for solving for the two foundational challenges of creating oligonucleotide-based medicines (OBMs) - safety and delivery** • Overview of connecting purpose-built pharmacology data with deep biophysical understanding of the molecules with ML/AI • Advances in using aptamers to target OBMs to tissues and cells CHRISTOPHER HART, Chief Executive Officer, **Creyon Bio**
13:15	LUNCH BREAK — 1-2-1 Meetings x3 — Poster Displays		

DAY TWO: OCTOBER 04 2024

TRACK 1: COMPUTATIONAL TOOLS, AI/ML-GUIDED ENGINEERING

14:15

Structure Empowered IMPACT Platform In The Discovery & Development Of Immunoglobulin Sculpting (IgSc) Enzyme & Dual-Cell Bidirectional (DcB) Antibody Drugs For Immunological Diseases

- Overview of structural biology function and IMPACT platform at Seismic
- Case study of how DcB antibody-antigen structures supported the development of biologic drugs
- Case study of how structure-based rational design and ML design fueled drug discovery and development of IgSc enzyme

YI XING, Senior Director,
Seismic Therapeutics

Q& A session & transition time between conference rooms

14:40

Panel Discussion: Understanding When & How to Scale Up CMC Effectively

- Safety & efficacy considerations
- AI/ML approaches to simplify CMC processes
- Small vs large company scale up: what are the differences?

Panelists:
JULIE BEAUDET, CMC Senior Staff Scientist, **Regeneron**

BRANDON COYLE, Senior Research Scientist II, **Gilead Sciences**

PURBASA PATNAIK, Associate Director, Drug Product Manufacturing & CMC Biotherapeutics, Exelixis

15:05

15:30

Impacts Of Drug-Linker Chemotype On The Analytical Development Of ADC Therapeutics

The drug-linker (DL) component of an ADC confers cytotoxicity-based mechanism of action to the therapeutic, and contributes to its physical behavior in analytical assays. Novel DL chemotypes present challenges to existing platforms and can prove to be obstacles to existing analytical control strategies. We present here approaches that address impacts of DL chemotype on the biochemical analysis of ADCs

JAY JONES, Senior Research Associate,
Pfizer

Q&A session & transition time between conference rooms

15:55

CMC Regulatory Landscape For Antibody Drug Conjugates

- Overview of current regulatory landscape
- Considerations for life-cycle development
- Novel considerations for antibody drug conjugates

JULIE BEAUDET, CMC Senior Staff Scientist,
Regeneron

16:20

End of Congress

TRACK 2: TRANSLATIONAL, CLINICAL & MANUFACTURING LESSONS

Panel Discussion: A Multi-Pronged Strategy For A Multipartite Molecule: The IP Space For ADCs

- Using multi-pronged and coordinated patent strategies to maximize global patent and regulatory exclusivities
- Topics include: recent ADC litigations, strategies for patent portfolio building and management, assessing freedom-to-operate, and monitoring the competitive landscape

Panellists:
LINDA HORNER, Acting Senior Lead Administrative Patent Judge, Patent Trial and Appeal Board, **USPTO**

LI FENG, Partner, **Finnegan**

JEAN GE, Patent Attorney, **Wolf Greenfield**

SYLVIA YIP, IP Counsel, **Zentalis**

Q& A session & transition time between conference rooms

Understanding The Relationship Between Delivery Vehicle Affinity & siRNA Mediated Knock Down

Understanding the relationship between antibody affinity of Antibody Oligo Conjugates (AOCs) and gene knock down in vitro and in vivo.

JACK OSTROWSKI, Director Protein Sciences,
Avidity Biosciences

Q&A session & transition time between conference rooms

Delegates are welcome to attend co- located events

Q&A session & transition time between conference rooms

Recent Progress With Antibody PMO Conjugates

Utilizing TfR1 receptor-mediated delivery of oligonucleotides to muscles presents a promising treatment strategy for muscular diseases such as DM1, DMD, and FSHD. Avidity's innovative Antibody Oligonucleotide Technology (AOC) holds significant potential for delivering phosphorodiamidate morpholino oligonucleotides (PMO) to muscle tissue, showcasing its applicability in the treatment of Duchenne Muscular Dystrophy (DMD). The presentation includes preclinical and clinical data on AOC 1044, an exon 44 skipping PMO conjugate.

MICHAEL COCHRAN, Director – Chemistry,
Avidity Biosciences

TRACK 3: PEPTIDE DISCOVERY, FORMULATION & DEVELOPMENT

Cystine-knot Peptide Inhibitors Of The Protease HTRA1 For The Treatment of Age-Related Macular dDegeneration

- **Cystine-knot peptides (CKPs) are naturally occurring and highly stable peptides**
- phage-displayed CKP libraries were used to identify inhibitors of HTRA1, a protease implicated in age-related macular degeneration
- phage-displayed CKP libraries were used to identify inhibitors of HTRA1, a protease implicated in age-related macular degeneration
- Hit optimization led to highly selective and potent picomolar inhibitors
- Crystal structures and biochemical studies revealed the intriguing details of the inhibitory mechanism and exceptional selectivity of the CKPs

DANIEL KRICHHOFER, Senior Fellow,
Genentech

Q&A session & transition time between conference rooms

Process Mass Intensity: A Holistic Analysis in Current Peptide Manufacturing Processes, Informing Sustainability in Peptide Synthesis

- Comparison of PMI across various manufacturing methods, including solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS)
- Identifying key areas for process optimization, including purification strategies and solvent selection
- Examination of solvent usage and exploration of solutions to mitigate environmental impact while maintaining process efficiency and product quality

PAUL RICHARDSON, Director Discovery Chemistry,
Pfizer

Q&A session & transition time between conference rooms

Allosteric GPCR Modulation With Peptides

STEVEN BALLET, Professor, Departments of Chemistry & Bio-Engineering Sciences,
Vrije Universiteit Brussel

Q&A session & transition time between conference rooms

Delegates are welcome to attend co- located events

Delegates are welcome to attend co- located events

BE PART OF SOMETHING EXCEPTIONAL

Venue Information

Westin San Diego Gaslamp Quarter

The Westin San Diego Gaslamp Quarter

910 Broadway Circle

San Diego, 92101

California

The Westin San Diego Gaslamp Quarter sits in the heart of the city's excitement, located near the Gaslamp quarter home to over 150 restaurants, cafes, bars, and shops. The Westin is also steps away from the San Diego Convention centre, Little Italy and Pecto Park. Within a 10 minute drive, you can also explore nearby beaches and attractions at the San Diego Zoo, Mission Beach's Belmont Park and SeaWorld San Diego.

Oxford Global has secured a number of bedrooms at the The Westin San Diego Gaslamp Quarter at a reduced conference rate:

Wednesday October 2nd 2024 – $315 (includes room rate & taxes)

Thursday October 3rd 2024 – $315 (includes room rate & taxes)

Should you wish to book a room, please click here

The final cut-off date to book bedrooms is Wednesday September 11th 2024 – any bookings after this date are subject to availability and rates. Please note, that any cancellations within 14 days prior to arrival are subject to cancellation charges.

Please **click here to visit the venue's website**
& to recieve more information on
The Westin San Diego Gaslamp Quarter

Book Now

Enabling the swift progression of complex, alternative drug formats to market through safe, effective & targeted formulation and delivery strategies

Register as an Industry Delegate

If you represent a pharma or biotech research organization primarily focused on therapeutic pipeline development, click here to secure your pass.

Register as an Academic Delegate

If you represent an academic institution and are involved in research and development, click here to request a pass.

Register as a Vendor Delegate

If you represent solution, technology, or service providers, commercial entities, consultants, or venture capitalists with a stake in the relevant landscapes, click here to secure your attendance

LinkedIn

@OGConferences

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!

Welcome to the future of life sciences engagement!

Effortless On-Demand Presentations

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

Beneficial Partnerships and Accelerated Learning

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic in-person and online events that drive professional growth.

Year-Round Exclusive Insights

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Featuring content & recordings from all Oxford Global brands:

- BIOLOGICS BY OXFORD GLOBAL
- BIOMARKERS BY OXFORD GLOBAL
- CELL & GENE BY OXFORD GLOBAL
- DISCOVERY BY OXFORD GLOBAL
- FORMULATION & DELIVERY BY OXFORD GLOBAL
- IMMUNO BY OXFORD GLOBAL
- OMICS BY OXFORD GLOBAL

Digital Pass

£459 +VAT

$700 +VAT

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com

BROCHURE CONTENTS

Book Now

LinkedIn

@OGConferences

BIOLOGICS SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.

Biologics 2024
13 - 15 March 2024
London, UK

Vaccines & Immunotherapies: Online Symposium
26 September 2024 | BST (UTC+1)

Oligo Chemistry & Therapeutics: Online Symposium
27 September 2024 | BST (UTC+1)

Biologics US 2024
03 - 04 October 2024
San Diego, CA

Antibody Engineering with Novel Technologies & Approaches: Online Symposium
20 November 2024 | GMT (UTC+0)

Biomarkers Series
Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series
Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series
Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series
Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series
Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets & Cell Types in Immuno-Oncology

Omics Series
Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/ to explore our diverse portfolio of events across 2024.

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Oxford Global PLUS Pass includes unrestricted access to all events shown above and much more

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com

BROCHURE CONTENTS

Book Now

LinkedIn
@OGConferences